Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gutcare
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Gutcare is a dual-strain probiotic formulation containing *Bifidobacterium* (specifically *Bifidobacterium longum*) and *Clostridium butyricum*. It is designed to restore and maintain a healthy intestinal microflora balance. *Clostridium butyricum* is a gram-positive, anaerobic spore-forming bacterium that produces butyric acid, a short-chain fatty acid that supports the health of the intestinal lining and exerts anti-inflammatory effects. *Bifidobacterium* species are key components of the healthy human gut microbiome, known for inhibiting the growth of pathogenic bacteria and enhancing immune function. In clinical research, specifically a randomized trial conducted in Kabul by Professor Mansoor Aslamzai, Gutcare was evaluated for its potential to reduce feeding intolerance and improve weight gain in preterm and low birth weight neonates when used as a fortifier for breast milk.
- Brand names
- Gutcare
- Other names
- Bifidobacterium longum + Clostridium butyricumBifidobacterium + Clostridium butyricum
Beyond the preview
Go deeper on Gutcare.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gutcare.